Cargando…
Dalbavancin: novel candidate for COVID-19 treatment
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Nature Singapore
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816554/ https://www.ncbi.nlm.nih.gov/pubmed/33473156 http://dx.doi.org/10.1038/s41422-020-00459-5 |
| _version_ | 1783638465834909696 |
|---|---|
| author | Hoffmann, Markus Jin, Yeonhwa Pöhlmann, Stefan |
| author_facet | Hoffmann, Markus Jin, Yeonhwa Pöhlmann, Stefan |
| author_sort | Hoffmann, Markus |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7816554 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer Nature Singapore |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78165542021-01-21 Dalbavancin: novel candidate for COVID-19 treatment Hoffmann, Markus Jin, Yeonhwa Pöhlmann, Stefan Cell Res Research Highlight Springer Nature Singapore 2021-01-20 2021-03 /pmc/articles/PMC7816554/ /pubmed/33473156 http://dx.doi.org/10.1038/s41422-020-00459-5 Text en © The Author(s) 2021, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Research Highlight Hoffmann, Markus Jin, Yeonhwa Pöhlmann, Stefan Dalbavancin: novel candidate for COVID-19 treatment |
| title | Dalbavancin: novel candidate for COVID-19 treatment |
| title_full | Dalbavancin: novel candidate for COVID-19 treatment |
| title_fullStr | Dalbavancin: novel candidate for COVID-19 treatment |
| title_full_unstemmed | Dalbavancin: novel candidate for COVID-19 treatment |
| title_short | Dalbavancin: novel candidate for COVID-19 treatment |
| title_sort | dalbavancin: novel candidate for covid-19 treatment |
| topic | Research Highlight |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816554/ https://www.ncbi.nlm.nih.gov/pubmed/33473156 http://dx.doi.org/10.1038/s41422-020-00459-5 |
| work_keys_str_mv | AT hoffmannmarkus dalbavancinnovelcandidateforcovid19treatment AT jinyeonhwa dalbavancinnovelcandidateforcovid19treatment AT pohlmannstefan dalbavancinnovelcandidateforcovid19treatment |